Prism Research LLC dba Nucleus Network — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$321,350	24
2024	Research	$3,874,379	50
2023	Research	$1,756,109	54
2022	Research	$2,671,229	34
2021	Research	$252,805	13

Breakdown

Who paid Research payments · program years 2021–2025

Pfizer Inc. $7,531,118 155 payments
Deciphera Pharmaceuticals Inc. $1,317,693 17 payments
Amgen Inc. $27,062 3 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 1 Randomized Openlabel 3Period 3Treatment 6Sequence Crossover Singledose Study in Healthy Adult Participants to Estimate the Bioavailability of the Registration Tablets of Vepdegestrant Arv471 Pf07850327 Relative to the Phase 3 Tablets $3,376,594 10 payments
A Phase 1 Study to Evaluate the Pharmacokinetics of Dcc-3014 in Healthy Adult Participants $1,317,693 17 payments
A Phase 1 Openlabel Randomized Single Dose 2Way Crossover Study Assessing Pharmacokinetic Comparability of Two Pf06881894 Presentations Onbody Injector and Prefilled Syringe in Healthy Participants $1,300,852 7 payments
A Phase 1 Randomized Doubleblind Sponsoropen Placebocontrolled Doseescalating Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Single and Multiple Intravenous and Subcutaneous Doses of Pf07264660 in Healthy Participants $1,052,857 25 payments
A Phase 1 Randomized and Phase 2 Study to Evaluate the Safety Tolerability Immunogenicity and Immunopersistence of A Clostridioides Difficile Vaccine Administered in A 2Dose Regimen With Novel Adjuvants in Healthy Adults $713,557 30 payments
A Phase 1 Openlabel Singledose Parallelgroup Study to Evaluate the Pharmacokinetics of Pf07081532 in Adult Participants With Type 2 Diabetes Mellitus With Varying Degrees of Renal Impairment Relative to Participants Without Renal Impairment $209,856 12 payments
A Phase 1 Nonrandomized Openlabel Study to Assess the Pharmacokinetics Safety and Tolerability of Pf07817883 in Adult Participants With Renal Impairment and Healthy Adult Participants With Normal Renal Function $196,119 13 payments
A Phase 1 Nonrandomized Openlabel Study to Assess the Pharmacokinetics Safety and Tolerability of Pf07321332 Boosted With Ritonavir in Adult Participants With Moderate Hepatic Impairment and Healthy Participants With Normal Hepatic Function $175,941 11 payments
A Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccines Against Influenza in Healthy Adults $151,600 15 payments
A Phase 1 Openlabel Nonrandomized Singledose Parallel Group Study to Evaluate the Pharmacokinetics Safety and Tolerability of Pf07923568 in Adult Participants With Renal Impairment and Healthy Adult Participants With Normal Renal Function $110,482 8 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.